Analysis of the clinicopathological characteristics and prognosis of triple-positive breast cancer and HER2-positive breast cancer—A retrospective study

Analysis of the clinicopathological characteristics and prognosis of triple-positive breast cancer and HER2-positive breast cancer—A retrospective study

BackgroundAdjuvant chemotherapy and targeted therapy have become standard postoperative therapeutic modalities for human epidermal growth factor receptor 2 (HER2)-positive breast cancer(HER2-positive,HR-negative), including triple-positive breast cancer(HER2-positive,HR-positive). However, these two...

Full description

Bibliographic Details
Main Authors:	Dongxu Ma, Qing Yang, Ke Yin, Peng Shi, Xiao Chen, Tianyi Dong, Xingchen Shang, Xingsong Tian
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-01-01
Series:	Frontiers in Oncology
Subjects:	triple-positive breast cancer HER2-positive breast cancer clinicopathological characteristics prognosis hormone receptors adjuvant chemotherapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2022.999894/full

Similar Items

Evolving Role of Risk Tailored Therapy in Early Stage HER2-Positive Breast Cancer: A Canadian Perspective
by: Sharon F. McGee, et al.
Published: (2022-06-01)

Ultrafast dynamic contrast-enhanced breast MRI with quantitative perfusion parameters in differentiating breast cancer: a study focusing on triple-negative and HER2 positive breast cancer
by: Guo Haodong, et al.
Published: (2025-01-01)

Triple-negative and Her2-positive breast cancer in women aged 70 and over: prognostic impact of age according to treatment
by: Gilles Houvenaeghel, et al.
Published: (2023-12-01)

HER2-targeted therapies for HER2-positive early-stage breast cancer: present and future
by: Luying Xu, et al.
Published: (2024-09-01)

Recurrent Metaplastic Breast Cancer with Subtype Converted from Triple-Negative to HER2-Positive: A Case Report and Literature Review
by: Wu J, et al.
Published: (2023-01-01)

Pharmacoeconomic analysis of pertuzumab in treatment of HER2-positive breast cancer in Ukraine
by: О. В. Мужичук, et al.
Published: (2021-03-01)

Clinicopathological features and prognosis of patients with HER2-low breast cancer
by: Xin Yang, et al.
Published: (2023-09-01)

Male HER-2 positive metastatic breast cancer: A case report
by: Na Lin, et al.
Published: (2020-12-01)

Impact of Location of Residence and Distance to Cancer Centre on Medical Oncology Consultation and Neoadjuvant Chemotherapy for Triple-Negative and HER2-Positive Breast Cancer
by: Elliott K. Yee, et al.
Published: (2024-08-01)

Clinicopathological characteristics and long-term prognosis of triple-negative breast cancer patients with HER2-Low expression: a retrospective propensity score-matched cohort study
by: Xin Liu, et al.
Published: (2024-12-01)

Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancer
by: Li S, et al.
Published: (2018-09-01)

Efficacy and Safety Profile of Different Schedules of Adjuvant Trastuzumab Therapy among Patients with HER2-Positive Breast Cancer: Real-World Experience from a Tertiary Cancer Center in South India
by: Nandini Devi Rajan, et al.

Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
by: Volkmar Müller, et al.
Published: (2018-03-01)

Real-World Study of Adjuvant Biosimilar Trastuzumab-dkst for HER2-Positive Breast Cancer Treatment in a Brazilian Population
by: Debora Gagliato, et al.
Published: (2024-06-01)

PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening
by: Jangsoon Lee, et al.
Published: (2021-06-01)

EXPERIENCE OF USING PERTUZUMAB IN ANTICANCER THERAPY FOR HER2-POSITIVE BREAST CANCER
by: O. I. Kit, et al.
Published: (2021-05-01)

Clinicopathological Characteristics and Androgen Receptor Expression of Triple Negative Breast Cancer: A Retrospective Study in Upper Egypt
by: Eman Mostafa Masoud*, et al.
Published: (2021-08-01)

Study on clinicopathological features and prognosis of HER2 low expression breast cancer
by: RUAN Miao, DA Qian, XU Haimin, DONG Lei, FEI Xiaochun
Published: (2024-10-01)

HER2-positive breast cancer – Available anti-HER2 therapies and new agents under investigation
by: Martyna Zielińska, et al.
Published: (2020-06-01)

Clinicopathological characteristics and prognosis of early-stage HER2 low-expression breast cancer: A single-center retrospective study
by: Chang-Gen Liu, et al.
Published: (2023-03-01)

The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer
by: Zaid Sirhan, et al.
Published: (2022-07-01)

Benefits of neoadjuvant therapy compared with adjuvant chemotherapy for the survival of patients with HER2-positive breast cancer: A retrospective cohort study at FUSCC
by: Shuyue Zheng, et al.
Published: (2022-06-01)

Prevalence of Cardiotoxicity Secondary to Trastuzumab in Patients with HER-2-Positive Breast Cancer in Southeast Mexico
by: Luz I. Pascual-Mathey, et al.
Published: (2024-09-01)

A new paradigm for classifying and treating HER2‐positive breast cancer
by: Xuexin He, et al.
Published: (2023-08-01)

Postneoadjuvant therapy: a new approach to the treatment of HER2-positive breast cancer (KATHERINE study results)
by: L. G. Zhukova, et al.
Published: (2019-12-01)

Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial
by: Ines Stevic, et al.
Published: (2018-10-01)

Comparison of clinicopathological characteristics, efficacy of neoadjuvant therapy, and prognosis in HER2-low and HER2-ultralow breast cancer
by: Feng Guan, et al.
Published: (2024-09-01)

Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines
by: Anne Julienne Genuino, et al.
Published: (2019-11-01)

HER2-Positive Metaplastic Breast Cancer with Resistance to Neoadjuvant Chemotherapy: Case Report
by: Kaho Tateishi, et al.
Published: (2023-11-01)

Multigene expression signatures in early hormone receptor positive HER 2 negative breast cancer
by: Ovcaricek Tanja, et al.
Published: (2019-09-01)

Strategy and Status of Neoadjuvant Therapy for HER2-positive Breast Cancer
by: LIU Yunjiang, et al.
Published: (2024-01-01)

Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain
by: Daniel Rayson, et al.
Published: (2022-12-01)

Not all small HER2 positive breast cancers have the same clinical outcome in the North-East of Scotland
by: Karola Pawloy, et al.
Published: (2022-01-01)

Safety and efficacy of T-DM1 in patients with advanced HER2-positive breast cancer The Royal Marsden experience
by: Nicolò Matteo Luca Battisti, et al.
Published: (2020-01-01)

A Retrospective, Observational Study to Determine the Patient and Tumor Characteristics of HER2-Positive Breast Cancer Patients Treated at Five Main Public Cancer Centers in Malaysia
by: Ros Suzanna Ahmad Bustamam, et al.
Published: (2020-01-01)

Trastuzumab resistance in HER2-positive breast cancer: Mechanisms, emerging biomarkers and targeting agents
by: Zhen-hao Wang, et al.
Published: (2022-10-01)

Current approaches in treatment of triple-negative breast cancer
by: Hanan Ahmed Wahba, et al.
Published: (2015-06-01)

Real-life analysis of neoadjuvant-therapy-associated benefits for pathological complete response and survival in early breast cancer patients - role of trastuzumab in HER2+ BC and platinum in TNBC
by: Wei-Pang Chung, et al.
Published: (2023-01-01)

Advances in Antibody-Drug Conjugates in the Treatment of HER2-Positive Breast Cancer
by: Yu Y, et al.
Published: (2022-12-01)

The research progress of endocrine therapy combined with targeted therapy for triple-positive breast cancer
by: CAO Xiaoshan, CONG Binbin
Published: (2023-03-01)